

ARTICLE

The p.A897KfsX4 frameshift variation in desmocollin-2 is not a causative mutation in arrhythmogenic right ventricular cardiomyopathy

Marzia De Bortoli¹, Giorgia Beffagna¹, Barbara Bauce², Alessandra Lorenzon¹, Gessica Smaniotto¹, Ilaria Rigato², Martina Calore¹, Ilena EA Li Mura¹, Cristina Basso³, Gaetano Thiene³, Gerolamo Lanfranchi^{1,4}, Gian Antonio Danieli¹, Andrea Nava² and Alessandra Rampazzo^{*,1}

Mutations in genes encoding desmosomal proteins have been reported to cause arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), an autosomal-dominant disease characterised by progressive myocardial atrophy with fibro-fatty replacement. We screened 112 ARVC/D probands for mutations in desmocollin-2 (*DSC2*) gene and detected two different amino-acid substitutions (p.E102K, p.I345T) and a frameshift variation (p.A897KfsX4) in 7 (6.2%) patients. *DSC2a* variant p.A897KfsX4, previously reported as a p.E896fsX900 mutation, was identified in five unrelated probands. Four of them were found to carry one or two mutations in different ARVC/D genes. Unexpectedly, p.A897KfsX4 variation was also found in 6 (1.5%) out of 400 control chromosomes. *In vitro* functional studies showed that, unlike wild-type *DSC2a*, this C-terminal mutated protein was localised in the cytoplasm. p.A897KfsX4 variation affects the last five amino acids of the *DSC2a* isoform but not of *DSC2b*. In contrast with what we found in other human tissues, in the heart *DSC2b* is more expressed than *DSC2a*, suggesting that relative deficiency of *DSC2a* might be compensated by isoform b. In conclusion, *DSC2* gene mutations are not frequently involved in ARVC/D. The p.A897KfsX4 variation, identified in several Italian healthy control subjects, which affects only one of the two *DSC2* isoforms, may be considered a rare variant, though possibly affecting phenotypic expression of concomitant ARVC/D mutations.

European Journal of Human Genetics (2010) 18, 776–782; doi:10.1038/ejhg.2010.19; published online 3 March 2010

Keywords: sudden death; ARVC/D; desmosome; *DSC2*; polymorphism

INTRODUCTION

Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) (MIM #107970) is an inherited disorder characterised by progressive fibro-fatty replacement of the right ventricular myocardium.¹ Clinical manifestations occur most often between the second and fourth decades of life and are characterised by ventricular arrhythmias, heart failure and sudden death. The disease usually shows autosomal-dominant inheritance with reduced penetrance,² although autosomal-recessive transmission has also been reported in Naxos Syndrome.³

Eight genes have been detected so far as being independently involved in the pathogenesis of the disease. Five of them encode major desmosomal proteins: plakoglobin (MIM *173325),^{3,4} desmoplakin (MIM *125647),⁵ plakophilin-2 (MIM *602861),⁶ desmoglein-2 (MIM *125671)⁷ and desmocollin-2 (MIM *125645).^{8,9} The involvement of such genes led to the current idea that ARVC/D is a disorder caused mainly by defects in cell–cell adhesion.

Other three nondesmosomal genes have been associated with ARVC/D: cardiac ryanodine receptor 2 (RYR2; MIM 180902),¹⁰ transforming growth factor beta-3 (TGFβ3; MIM 190230)¹¹ and transmembrane protein 43 (TMEM43; MIM 612048).¹²

To date, five different *DSC2* mutations have been reported: two frameshift mutations p.M477fsX480 and p.E896fsX900,⁸ a heterozygous splice acceptor site mutation c.631-2A>G⁹ and two missense

mutations p.E102K and p.I345T.¹³ *In vitro* functional studies showed that the two point mutations affect the intracellular localisation of *DSC2a*, thus suggesting a potential pathogenic effect.¹³ More recently, a homozygous mutation p.S614fsX625 in *DSC2* gene associated with autosomal-recessive ARVC/D, mild palmoplantar keratoderma and woolly hair has been described.¹⁴

In this study, we investigated the frequency of *DSC2* mutations in an unselected Italian ARVC/D patient cohort. In five probands, we have identified the frameshift p.A897KfsX4 variation (previously reported as p.E896fsX900⁸), which was also detected among Italian healthy control subjects. On the basis of genetic and functional data, we discuss here the pathogenic role of the p.A897KfsX4 variation.

MATERIALS AND METHODS

Mutation screening

A total of 112 ARVC/D unrelated index cases were screened for *DSC2* mutations by denaturing high-performance liquid chromatography and direct sequencing. This patient group includes 54 subjects already reported in a previous study.¹³ The coding region of *DSR*, *PKP2* and *DSG2* genes was screened for mutations in *DSC2* mutation carriers.

A control group of 200 healthy and unrelated Italian subjects (400 alleles) was used to exclude that identified mutations could be DNA polymorphisms. All controls were matched to the probands by ancestry and underwent ordinary clinical investigations.

¹Department of Biology, University of Padua, Padua, Italy; ²Department of Cardio-thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy; ³Department of Medico-Diagnostic Sciences and Special Therapies, University of Padua Medical School, Padua, Italy; ⁴CRIBI Biotechnology Centre, University of Padua, Padua, Italy
*Correspondence: Dr A Rampazzo, Department of Biology, University of Padua, via Ugo Bassi 58/B, 35131 Padua, Italy. Tel: +39 049 8276208; Fax: +39 049 8276209; E-mail: alessandra.rampazzo@unipd.it

Received 14 July 2009; revised 7 January 2010; accepted 26 January 2010; published online 3 March 2010

Mutation screening was performed in all available family members of index cases in which a *DSC2* mutation was detected.

Comparison of p.A897KfsX4 variant in patients and control subjects was assessed by one-tail Fisher's exact test. A *P*-value <0.05 was considered statistically significant.

Clinical study

Each patient underwent physical examination and family history, 12-lead electrocardiography (ECG), signal-averaged ECG, 24-h Holter ECG and two-dimensional echocardiography. A clinical diagnosis of ARVC/D was based on major and minor criteria, established by the European Society of Cardiology/International Society and Federation of Cardiology Task Force.¹⁵ Informed consent for clinical investigations and blood sampling for DNA analysis was obtained from all participating individuals, according to the pertinent Italian legislation and in compliance with the Helsinki declaration.

Haplotype analysis

DNA samples of all frameshift variation carriers were assessed for a common haplotype using the following microsatellite markers: D18S847, D18SH3, D18SH4 and D18S36. Markers D18SH3 and D18SH4 are new polymorphic tri- and dinucleotide repeats that we identified starting at positions 26755775 and 26908386, respectively, on chromosome 18q12.1 (Human Genome Browser, <http://genome.ucsc.edu/>). They were amplified using the primers D18SH3F 5'-GTGGTGGGCATCTGTAATCC-3', D18SH3R 5'-GGTGCCTGCGTTTAGTA T-3', D18SH4F 5'-CTCCCTTATGACCCAGGAAA-3' and D18SH4R 5'-ACCAT GTGGGAAACCAAT-3' under standard PCR conditions. D18SH4 is within the *DSC2* intron 12, whereas the other three markers are in close proximity to the *DSC2* locus. Forward primers were fluorescently labelled. In particular, D18S847 and D18SH3 were labelled with TAMRA, D18SH4 with HEX and D18S36 with FAM. Amplification products were pooled into a post-amplification panel, mixed with GeneScan ROX400 size standard (Applied Biosystems, Foster City, CA, USA). Capillary electrophoresis was carried out on an ABI PRISM 3730XL DNA sequencer (Applied Biosystems) and Genotyper V3.5 analysis software (Applied Biosystems) was used to analyse each amplicon.

Expression pattern of *DSC2* isoforms

Expression of *DSC2a* and *DSC2b* isoforms in different human tissues was examined by PCR amplification of cDNAs including the heart, brain, placenta, lung, skeletal muscle, liver, kidney and pancreas (Multiple Tissue cDNA panel I, Clontech, Palo Alto, CA, USA). Amplification was performed by using primers previously reported.¹⁶ The splice form 'b' resulted in a PCR fragment of 500 bp, whereas splice form 'a' produced a 454 bp fragment.

Site-directed mutagenesis

PCR-based site-directed mutagenesis was performed on wild-type *DSC2a*-pCDNA3.1/CT-GFP, already available to the study,¹³ to obtain three new constructs. Each construct differs from the others for a variation introduced in the human *DSC2*-coding region: an insertion c.2687_2688insGA leading to the frameshift variation p.A897KfsX4, and two nucleotide substitutions c.536A>G (p.D179G) and c.2393G>A (p.R798Q), which happened to be common polymorphisms. The following mutagenic primers were used: *DSC2*D179G: 5'-TCCATAAGAGGTCCTGGAGTTGGCCAAGAACCCGGAAT TTAATTTT-3'; *DSC2*R798Q: 5'-CACCAGACCTCGGAATCCTGCCAGGGGG CTGCCACCATCACACC-3'; *DSC2*insGA: 5'-CAAATTTGGACACTAGCAGAG AAGCATGCATGAAGAGACAAG-3' and *DSC2*frameGA: 5'-CACTAGCAGAG AAGCATGCACAAGGGCAATTCTGCAGATA-3'. Two steps of mutagenesis were necessary to obtain a construct coding for p.A897KfsX4 variation, the first to introduce the GA insertion and the second to remove the premature stop codon and the following 5 nucleotides to get the right frame with GFP sequence. Thus, the mutant construct does not contain additional amino acids compared with the wild type. The coding regions of each mutant construct were fully sequenced.

Cell culture and transfection

HL-1 cells, kindly provided by Dr WC Claycomb (New Orleans), were used and maintained as previously reported.¹⁷ Cells were cultured at 37°C in 5% CO₂.

Constructs corresponding to wild type or to a variant of human *DSC2a* were transiently transfected in HL-1 cells at a confluence of 70–80%, using Effectene reagent (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Transfected cells were incubated for 48 h to allow protein expression and desmosome formation.

Immunostaining and confocal imaging

HL-1 cells were fixed with cold methanol/acetone (1:1) and immunostained for endogenous desmoglein with the murine mAb (clone DG3.10) as previously described in detail.¹³ Images were acquired with a Radiance 2000 confocal microscope (BioRad, Hercules, CA, USA) with a ×60 oil objective.

RESULTS

Mutation screening

DSC2 mutation screening was performed in a series of 112 consecutive unrelated index cases. Two different amino-acid substitutions (p.E102K, p.I345T) and a frameshift (p.A897KfsX4) have been detected in seven (6.2%) patients (Figure 1a). We also identified two polymorphisms (c.536A>G and c.2393G>A, allele frequency 2.7 and 4.7%, respectively) in exon 5 and in exon 15, resulting in predicted p.D179G (novel) and p.R798Q (rs61731921) amino-acid substitutions.

The two missense mutations p.E102K and p.I345T, previously reported by our group,¹³ affect the normal localisation of mutant proteins in cultured cardiomyocytes. The frameshift variation p.A897KfsX4, primarily reported as p.E896fsX900 by Syrris *et al*,⁸ causes a premature termination of the protein. Only the last five amino acids of *DSC2a* were altered: three were changed and the last two were lost (Figure 1b). The five involved amino-acid residues are




Figure 1 (a) p.E102K and p.I345T mutations (black arrows) and p.A897KfsX4 variation (red arrow) identified in the *DSC2* gene. p.A897KfsX4 variation affects only the *DSC2a* isoform. (b) Changes introduced in the amino-acid sequence of *DSC2a*, caused by the insertion c.2687_2688insGA in the *DSC2* gene. (c) The last five amino acids of *DSC2a* (involved by p.A897KfsX3 variation) show relative variance among the species: *Homo sapiens* (NP_077740), predicted *Macaca mulatta* (XP_001102096.1), predicted *Pan troglodytes* (XP_512077.2), predicted *Bos taurus* (XP_615164.3), *Rattus norvegicus* (NP_001028860.1), predicted *Canis familiaris* (XP_866917.1), predicted and *Equus caballus* (XP_001496356.1). The colour reproduction of the figure is available on the html full text version of the paper.

Table 1 A897KfsX4 variation carriers

Proband	Gene	Nucleotide change	Amino-acid change
1	DSC2	c.2687_2688insGA	p.A897KfsX4
2	DSC2	c.2687_2688insGA	p.A897KfsX4
	DSG2	c.260A>G	p.Y87C
3	DSC2	c.2687_2688insGA	p.A897KfsX4
	DSG2	c.1912G>A	p.G638R ^a
	DSP	c.1124A>T	p.N375I ^a
4	DSC2	c.2687_2688insGA	p.A897KfsX4
	PKP2	c.1211_1212insT	p.V406SfsX3
5	DSC2	c.2687_2688insGA	p.A897KfsX4
	DSP	c.1124A>T	p.N375I ^a
	PKP2	c.1655T>G	p.F552C ^a

^aIndicates novel mutations.

less conserved among mammals, in contrast with the high conservation of the upstream region (Figure 1c). DSC2b is not affected by the p.A897KfsX4 variation (Figure 1a), as it has a shortened C-terminal domain caused by a stop codon in the additional exon 16.

Five unrelated ARVC/D index cases (allele frequency 2.2%) were found to carry the p.A897KfsX4 variation, as well as 6 out of 200 control subjects (allele frequency 1.5%).

A 0.11 *P*-value, falling above the 0.05 significance threshold, indicates that there was no evidence of overrepresentation of the p.A897KfsX4 variant in patients compared with control subjects.

Mutations in other ARVC/D genes were identified in four of these five patients (Table 1). Proband 1 was found to carry the p.A897KfsX4 mutation and the previously reported PKP2 p.E58D common polymorphism.¹⁸ The allele frequency of the p.E58D variant in our control population was 0.9%, in contrast with the reported 5% in the Finnish population representing a genetic isolate.¹⁸

The additional detected mutations DSG2 p.Y87C and PKP2 p.V406SfsX3 have been previously reported as disease causing.^{19,20} None of the novel identified mutations (DSG2 p.G638R; DSP p.N375I; PKP2 p.F552C) were observed in 400 control chromosomes and occurred in residues that are highly conserved among species (data not shown). Moreover, they all lead to a change in biochemical properties of the amino acid involved.

In proband 4, it has also been identified a nucleotide substitution c.45C>T in the PKP2 gene, which causes a synonymous variation p.T15T. A total of 220 control alleles are negatives for this variation. This nucleotide substitution might be a rare polymorphism or it might activate a cryptic splice site and produce an aberrant transcript.

Clinical findings

Proband 1 was a 60-year-old woman who was diagnosed as having ARVC/D due to ECG abnormalities. A two-dimensional echocardiogram revealed a severe dilation of the right ventricle with depressed ventricular function. Moreover, frequent premature ventricular contractions with left bundle-branch block morphology were present at 24-h Holter ECG. The genetic analysis extended to her son revealed that he carries the *DSC2* frameshift variation p.A897KfsX4 and *PKP2* polymorphism p.E58D as well. Clinical evaluation showed the presence of some criteria also in the son, even if he did not fulfil the diagnosis (Table 2).

Proband 2 was diagnosed at the age of 45 with palpitations. The 24-h Holter ECG showed frequent episodes of non-sustained ventricular arrhythmias and imaging techniques showed a severe right ventricular dilation/dysfunction. He was found to be a double

heterozygote for the *DSC2* p.A897KfsX4 variation and the *DSG2* p.Y87C mutation. His daughter, clinically unaffected, is negative for both (Table 2).

Proband 3 experienced a sustained VT episode at the age of 38 years. Clinical and instrumental examination revealed at that time right ventricular abnormalities that became more evident during follow-up. She also carried a missense mutation in the *DSP* gene (p.N375I) and in the *DSG2* gene (p.G638R). The genetic study was extended to additional family members, and two subjects were double heterozygotes for the *DSG2* mutation and *DSC2* variation and one subject carried the *DSG2* mutation (Figure 2). One of the double heterozygotes (subject 3.(II,7)) carrying the *DSG2* p.G638R and *DSC2* p.A897KfsX4 fulfilled the ARVC/D diagnostic criteria, whereas the other family members were clinically unaffected (Table 2).

Proband 4 was a female patient who underwent cardiac evaluation due to several presyncopal episodes. The ECG showed negative T waves in V1–V4 and in inferior leads. Late potentials were present at 40–80 Hz. At two-dimensional echocardiogram, the right ventricle was mildly dilated with the presence of kinetic alterations; the 24-Holter ECG documented the presence of frequent premature ventricular contractions with left bundle-branch block morphology.

Cardiac magnetic resonance confirmed the presence of mild right ventricular dilatation and kinetic alterations, localised on the sub-tricuspid region and on the apex. The left ventricle was not involved. She was also found to carry the *PKP2* p.V406SfsX3 mutation and the *PKP2* p.T15T synonymous variation. The genetic analysis extended to her daughter revealed that she carries only the p.T15T variation in the presence of negative clinical and instrumental findings.

Proband 5 underwent cardiac evaluation at the age of 45 years, because of the presence of premature ventricular contractions detected during a pre-operative ECG that also showed intraventricular conduction delay and negative T waves in V4–V6. Signal-averaged ECG documented the presence of late potentials at all filter settings. The two-dimensional echocardiogram showed biventricular dimensional and kinetic abnormalities. At the age of 49, he received an implantable cardioverter defibrillator because of recurrent VT episodes. He was found to carry additional mutations in the other two ARVC/D genes: p.N375I in *DSP* and p.F552C in *PKP2*. His brother carries only the *DSP* mutation. The clinical and instrumental examination showed the presence of some ECG criteria, even if he did not fulfil the diagnosis (Table 2).

Haplotype analysis

In contrast with other reported *DSC2* mutations,^{8,9,13} p.A897KfsX4 is the only one identified in more Italian and English ARVC/D patients. Haplotype analysis was performed using four polymorphic microsatellites, one intragenic (D18SH4) and three in close proximity to the *DSC2* gene (D18S847, D18SH3 and D18S36). Different haplotypes segregated with the p.A897KfsX4 variation in each of the five Italian patients showing the absence of a founder effect for this variation (data not shown). This result confirms data reported by Syrris *et al*⁸ for their three families, suggesting that p.A897KfsX4 is a recurrent variation.

Expression pattern of *DSC2* isoforms

Almost all analysed human cDNA samples (heart, pancreas, lung, placenta, brain, skeletal muscle, liver and kidney) showed expression of both *DSC2* splice forms (Figure 3). It is interesting to note that all of them showed a different expression level of the two isoforms. In particular, in contrast with what we found in the other tissues, in the heart, isoform b is more expressed than isoform a.

Table 2 Clinical and genetic findings in A897KfsX4 variation carriers

Proband #. (family #)	Sex	Age at diagnosis/last follow-up	Family history		12-lead ECG				SAECG		Arrhythmias		RV		LV involved	Diagnostic criteria	Gene	Amino-acid change		
			Major	Minor	Negative T waves		Negative T waves		Epsilon wave		PVCs > 1000 per 24-h		NSVT						size/function	m
					precordial leads	inferior leads	inferior leads	incomplete RBBB	major	minor	SVT	LBBB	VF	M						
1	F	60	-	+	+	-	-	-	-	-	+	-	-	+	-	1M/3m	DSC2	A897KfsX4		
1.(1)	M	33	-	+	-	-	-	-	+	+	-	-	-	-	-	2m	DSC2	A897KfsX4		
2	M	45	-	-	+	+	-	-	-	-	+	-	-	-	-	1M/2m	DSC2	A897KfsX4		
2.(1)	F	22	-	+	-	-	-	-	-	-	-	-	-	-	-	1m	DSG2	Y87C		
3	F	38	-	-	+	+	-	-	-	+	-	-	-	-	+	1M/3m	DSC2	A897KfsX4		
3.(1),2	F	58	-	+	-	-	-	-	-	-	-	-	-	-	+	1m	DSC2	-		
3.(1),6	F	54	-	+	-	-	-	-	-	-	-	-	-	-	-	1m	DSC2	A897KfsX4		
3.(1),7	M	42	-	+	-	-	-	-	-	+	-	-	-	-	+	4m	DSC2	A897KfsX4		
4	F	30	-	+	+	+	-	-	-	np	+	-	-	+	-	4m	DSC2	A897KfsX4		
4.(1)	F	13	-	+	-	-	-	-	+	-	-	-	-	-	-	1m	PKP2	V406SfsX3		
5	M	45	-	-	+	+	+	+	-	+	-	-	-	+	+	1M, 3m	DSC2	A897KfsX4		
5.(1)	M	49	-	+	-	-	-	-	+	+	-	-	-	-	-	3m	DSC2	-		
																	DSP	N375I		
																	DSC2	F552C		
																	DSP	N375I		
																	PKP2	-		

Abbreviations: np, not performed; ECG, electrocardiography; SAECC, signal-averaged ECG; LBBB, left bundle-branch block; RBBB, right bundle-branch block; SVT, sustained ventricular tachycardia; PVC, premature ventricular contraction; VF, ventricular fibrillation; M, major diagnostic criteria; m, minor diagnostic criteria.
*paediatric ECG.




Figure 2 Pedigree of proband 3 (marked by an arrow). Filled-in symbols indicate clinically affected family members and white symbols indicate unaffected individuals. Absence (–) and presence of (#) *DSP*, (*) *DSG2* mutations and (●) *DSC2* variation are indicated.

The PCR products for heart tissue were verified and confirmed by sequencing (data not shown).

Functional analysis of C-terminal mutant *DSC2a* (p.A897KfsX4)

Site-directed mutagenesis was performed on wild-type construct encoding for a human *DSC2a*–GFP fusion protein to study the functional effect of the p.A897KfsX4 variation and of two *DSC2* polymorphisms, p.D179G and p.R798Q, located in the N- and C-terminal domains of the protein, respectively.

Constructs were transfected in the desmosome-forming cell line HL-1 having a differentiated cardiomyocyte phenotype and contractile activity *in vitro*. The GFP signal revealed a predominant localisation at the plasma membrane of wild type (Figure 4a) and proteins carrying p.D179G and p.R798Q polymorphisms (Figures 4b and c), displaying colocalisation with endogenous *dsg* at the cell membrane to indicate well-assembled desmosomes (Figure 4a'–c').

By contrast, protein-carrying frameshift variation p.A897KfsX4 was detected in the cytoplasm (Figure 4d), losing the proper desmosomal localisation along cell boundaries. However, endogenous *dsg* is normally well distributed (Figure 4d').

DISCUSSION

DSC2 was the most recent major component of the cardiac desmosome to be implicated in ARVC/D. *DSC2* gene encodes one of desmosomal cadherins, single-pass transmembrane glycoproteins able to mediate Ca^{2+} -dependent cell–cell adhesion, by interacting laterally and transcellularly with each other and by recruiting cytoplasmic plaque proteins that facilitate attachment of intermediate filaments.²¹

We have identified two different *DSC2* mutations and one *DSC2* variation in 7 out of 112 unrelated ARVC/D index cases, two already described in our previous report¹³ and p.A897KfsX4 originally referred to as a causative mutation.⁸ The frameshift variation was identified in five independent patients, four of whom are carriers for one or two mutations in known ARVC/D genes. Surprisingly, we found the same variation in several Italian controls with no significant difference in the distribution of the variant between the patients and control group.

By contrast, in the original paper reporting the identification of the p.A897KfsX4 variation, three probands carried only this frameshift variation, which was never identified in 200 control subjects.⁸

In contrast with other reported *DSC2* mutations, p.A897KfsX4 is the only one identified in several Italian and English ARVC/D patients. Haplotype analysis excludes a founder effect in our patients as well as in English cases and confirms that p.A897KfsX4 is a recurrent variation.




Figure 3 Expression pattern of *DSC2* splice forms. Double band represents isoform b (500 bp) and isoform a (454 bp). Results shown are from the heart (lane 1), pancreas (lane 2), lung (lane 3), placenta (lane 4), brain (lane 5), skeletal muscle (lane 6), liver (lane 7) and kidney (lane 8).

This variant occurs in exon 17 that encodes for the intracellular cadherin-like sequence (ICS) domain only in the splice variant 'a' of the *DSC2* gene, whereas the splice variant 'b' has a different C-terminal domain. ICS domain provides binding sites for other desmosomal constituents such as plakoglobin, plakophilin and desmoplakin.^{22–24} It has been shown that the latest 37 amino acid in *Dsc1a* are fundamental for plakoglobin binding in human epithelial A-431 cells.²³ On the other hand, *in vitro* functional studies on HL-1 cells have shown that *DSC2a*–GFP–A897KfsX4 protein localises in the cytoplasm, in contrast with wild-type protein and *DSC2a* variants carrying the polymorphism p.D179G or p.R798Q, which correctly colocalise at the cell membrane with endogenous desmoglein.

However, it is important to notice that the exon 17 is untranslated in the *DSC2b* isoform. Therefore, the insertion would affect only *DSC2a*, leaving isoform b fully functional and possibly able to compensate in cardiac myocytes the relative deficiency of the *DSC2a* isoform. Furthermore, in contrast with what we found in the other human tissues, in the heart, the *DSC2b* isoform is more expressed than *DSC2a*, supporting the hypothesis of a possible compensation by the isoform b.

Little is known about human *DSC2b* and in general about all *Dscb* isoforms; until now, a specific desmosomal interaction with PKP3 has been shown only for *Dsc3b*.²⁵ Moreover, PKP1, for which strong *in vitro* association with the 'a' form of *Dsc1* has been reported,²⁴ was also found to overlap with the 'b' form.²⁶ The possibility that *Dscb* isoforms contain a PKP-binding domain should be investigated further.

Four out of five patients carrying the p.A897KfsX4 variation also had one or two additional ARVC/D mutations. On the other hand, proband 1 carrying only the p.A897KfsX4 variation was also found to carry a reported polymorphism (PKP2 p.E58D) whose pathogenic role, if any, remains to be investigated.¹⁸ Moreover, we cannot exclude that this proband could have a large insertion, deletion or mutation in the non-coding regions of ARVC/D genes or also a mutation in unknown ARVC/D genes.

It may be hypothesised that the p.A897KfsX4 variation could act in the presence of other ARVC/D mutations as a factor able to modify their pathogenic effect. All probands showed moderate to severe forms of the disease, with biventricular involvement in some cases. However, in our study group, genotype–phenotype data could not give a clear indication of the role of this variant in the disease phenotype. Moreover, there is no different proportion




Figure 4 Functional studies in HL-1 cells. DSC2a-GFP-WT, DSC2a-GFP-D179G and DSC2a-GFP-R798Q were localised at the cell membrane between two HL-1 cells (**a–c**), whereas DSC2a-GFP-A897KfsX4 was detected in the cytoplasm (**d**). Immunostaining with monoclonal desmoglein antibody DG3.10 (**a'–d'**) showed both the presence of well-assembled desmosomes (yellow dots in **a'–c'**) and no colocalisation between endogenous dsg and DSC2a-GFP-A897KfsX4 (**d'**). The colour reproduction of the figure is available on the html full text version of the paper.

of the variant in the controls and affected subjects to provide evidence of an association between the disease and the variant. Assessment of the exact significance of the p.A897KfsX4 variation requires further studies in additional families carrying mutations in other ARVC/D genes.

Until now, few *DSC2* gene mutations were reported to cause ARVC/D. Among them, the p.A897KfsX4 variation, identified in several Italian healthy control subjects and altering only one of the two *DSC2* isoforms, could be considered a rare polymorphism that may affect the phenotypic expression of concomitant ARVC/D mutations.

Further clarification of the co-occurrence of mutations and rare polymorphisms in different desmosomal proteins could be an

important aspect in accounting for the known inter- and intrafamilial variable phenotypic expression.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This study was supported by Telethon, Rome (GGP07220); the Fifth Framework Programme European Commission (QLG1-CT-2000-01091); the Ministry of Health, MIUR (2006061007_002); and the Fondazione Cassa di Risparmio, Padova e Rovigo. The authors are deeply indebted to Paola Marcon for her help in collecting ARVC/D families.

- 1 Thiene G, Nava A, Corrado D, Rossi L, Pennelli N: Right ventricular cardiomyopathy and sudden death in young people. *N Engl J Med* 1988; **318**: 129–133.
- 2 Nava A, Thiene G, Canciani B *et al*: Familial occurrence of right ventricular dysplasia: a study involving nine families. *J Am Coll Cardiol* 1988; **12**: 1222–1228.
- 3 McKoy G, Protonotarios N, Crosby A *et al*: Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). *Lancet* 2000; **355**: 2119–2124.
- 4 Asimaki A, Syrris P, Wichter T, Matthias P, Saffitz JE, McKenna WJ: A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy. *Am J Hum Genet* 2007; **81**: 964–973.
- 5 Rampazzo A, Nava A, Malacrida S *et al*: Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. *Am J Hum Genet* 2002; **71**: 1200–1206.
- 6 Gerull B, Heuser A, Wichter T *et al*: Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. *Nat Genet* 2004; **36**: 1162–1164.
- 7 Pilichou K, Nava A, Basso C *et al*: Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. *Circulation* 2006; **113**: 1171–1179.
- 8 Syrris P, Ward D, Evans A *et al*: Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. *Am J Hum Genet* 2006; **79**: 978–984.
- 9 Heuser A, Plovie ER, Ellinor PT *et al*: Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. *Am J Hum Genet* 2006; **79**: 1081–1088.
- 10 Tiso N, Stephan DA, Nava A *et al*: Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). *Hum Mol Genet* 2001; **10**: 189–194.
- 11 Beffagna G, Occhi G, Nava A *et al*: Regulatory mutations in transforming growth factor-beta 3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. *Cardiovasc Res* 2005; **65**: 366–373.
- 12 Merner ND, Hodgkinson KA, Haywood AF *et al*: Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. *Am J Hum Genet* 2008; **82**: 809–821.
- 13 Beffagna G, De Bortoli M, Nava A *et al*: Missense mutations in desmocollin-2 N-terminus, associated with arrhythmogenic right ventricular cardiomyopathy, affect intracellular localization of desmocollin-2 *in vitro*. *BMC Med Genet* 2007; **8**: 65–75.
- 14 Simpson MA, Mansour S, Ahnood D *et al*: Homozygous mutation of desmocollin-2 in arrhythmogenic right ventricular cardiomyopathy with mild palmoplantar keratoderma and woolly hair. *Cardiology* 2008; **113**: 28–34.
- 15 McKenna WJ, Thiene G, Nava A *et al*: Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy: Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. *Br Heart J* 1994; **71**: 215–218.
- 16 Nuber UA, Schafer S, Schmidt A, Koch PJ, Franke WW: The widespread human desmocollin Dsc2 and tissue-specific patterns of synthesis of various desmocollin subtypes. *Eur J Cell Biol* 1995; **66**: 69–74.
- 17 Claycomb WC, Lanson NA, Stallworth BS *et al*: HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. *Proc Natl Acad Sci USA* 1998; **95**: 2979–2984.
- 18 Lahtinen AM, Lehtonen A, Kaartinen M *et al*: Plakophilin-2 missense mutations in arrhythmogenic right ventricular cardiomyopathy. *Int J Cardiol* 2008; **126**: 92–100.
- 19 Pilichou K, Nava A, Basso C *et al*: Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. *Circulation* 2006; **113**: 1171–1179.
- 20 van Tintelen JP, Entius MM, Bhuiyan ZA *et al*: Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circulation* 2006; **113**: 1650–1658.
- 21 Yin T, Green KJ: Regulation of desmosome assembly and adhesion. *Semin Cell Dev Biol* 2004; **15**: 665–677.
- 22 Troyanovsky SM, Eshkind LG, Troyanovsky RB, Leube RE, Franke WW: Contributions of cytoplasmic domains of desmosomal cadherins to desmosome assembly and intermediate filament anchorage. *Cell* 1993; **72**: 561–574.
- 23 Troyanovsky SM, Troyanovsky RB, Eshkind LG, Leube RE, Franke WW: Identification of amino acid sequence motifs in desmocollin, a desmosomal glycoprotein, that are required for plakoglobin binding and plaque formation. *Proc Natl Acad Sci USA* 1994; **91**: 10790–10794.
- 24 Smith EA, Fuchs E: Defining the interactions between intermediate filaments and desmosomes. *J Cell Biol* 1998; **141**: 1229–1241.
- 25 Bonn e S, Gilbert B, Hatzfeld M, Chen X, Green KJ, van Roy F: Defining desmosomal plakophilin-3 interactions. *J Cell Biol* 2003; **161**: 403–416.
- 26 North AJ, Bardsley WG, Hyam J *et al*: Molecular map of the desmosomal plaque. *J Cell Sci* 1999; **112**: 4325–4336.